Dopamine D2 Receptor Biased Signaling


Beaulieu JM etal 2015. Dopamine Receptors-IUPHAR Review 13. British J of Pharmacology 172: 1-23

Mailman RB and Murthy V 2010. Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity? Curr Pharm Des 16(5): 488-501

Lead Compounds: BBL1010 , BBL1020


Urs NM etal 2017. New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy. Biological Psychiatry 81(1): 78-85

Urs NM etal 2016. Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proc Natl Acad Sci USA 113(50): E8178-E8186

Park SM etal 2015. Effects of β-Arrestin_Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behaviour in Hypoglutamatergic Mice. Neuropsychopharmacology 41(3): 704–715

Fulmer T 2011. Arrestin Psychosis. Science-Business eXchange 4(44): doi:10.1038/scibx.2011.1224 Published online Nov. 10, 2011

Allen J etal 2011. Discovery of β-Arrestin_Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy. Proc Natl Acad Sci USA 108(45): 18488-18493